Functions of nuclear factor κb in bone

Annals of the New York Academy of Sciences

Volumn 1192, Issue , 2010, Pages 367-375

  Boyce, Brendan F ^a   Yao, Zhenqiang ^a   Xing, Lianping ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

NF B; Osteoblast; Osteoclast

Indexed keywords

CYTOKINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ASTHMA; AUTOCRINE EFFECT; BONE; BONE DISEASE; CONFERENCE PAPER; ENCHONDRAL OSSIFICATION; HUMAN; NONHUMAN; OSTEOBLAST; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 77950640257     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05315.x     Document Type: Conference Paper

References (60)

1. Karin, M. &F.R. Greten. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5: 749-759.
2. Courtois, G. &T.D. Gilmore. 2006. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25: 6831-6843.
3. Vallabhapurapu, S. &M. Karin. 2009. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27: 693-733.
4. Boyce, B.F. &L. Xing. 2007. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9(Suppl 1): S1.
5. Novack,D.V., L.Yin, A.Hagen-Stapleton, et al. 2003. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198: 771-781.
6. Hayden, M.S. &S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344-362.
7. Karin, M. 2008. The I-kappaB kinase kappa-a bridge between inflammation and cancer. Cell Res. 18: 334-342.
8. Dobrzanski, P., R.P. Ryseck &R. Bravo. 1995. Specific inhibition of RelB/p52 transcriptional activity by the Cterminal domain of p100. Oncogene 10: 1003-1007.
9. Liou, H.C., G.P. Nolan, S. Ghosh, et al. 1992. The NFkappaBp50 precursor, p105, contains aninternal I kappa B-like inhibitor that preferentially inhibits p50. EMBO J. 11: 3003-3009.
10. Palombella, V.J., O.J. Rando, A.L. Goldberg &T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing theNF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785.
11. Fusco, A.J., O.V. Savinova, R. Talwar, et al. 2008. Stabilization of RelB requires multidomain interactions with p100/p52. J. Biol. Chem. 283: 12324-12332.
12. Shibata,W., S.Maeda,Y.Hikiba, et al. 2007.Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury inmurine colitis. J. Immunol. 179: 2681-2685.
13. Bonizzi, G. &M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25: 280-288.
14. Senftleben, U., Y. Cao, G. Xiao, et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NFkappa B signaling pathway. Science 293: 1495-1499.
15. Yilmaz, Z.B., D.S. Weih, V. Sivakumar &F. Weih. 2003. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 22: 121-130.
16. Chaisson, M.L., D.G. Branstetter, J.M. Derry, et al. 2004. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J. Biol. Chem. 279: 54841-54848.
17. Xu, J.,H.F.Wu, E.S. Ang, et al. 2009. NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20: 7-17.
18. Franzoso, G., L. Carlson, L. Xing, et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11: 3482-3496.
19. Iotsova, V., J. Caamano, J. Loy, et al. 1997. Osteopetrosis in mice lacking NF-B1 andNF-B2. Nat.Med. 3: 1285-1289.
20. Xing, L.,T.P.Bushnell, L.Carlson, et al. 2002.NF-kappaB p50 and p52 expression is not required for RANKexpressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17: 1200-1210.
21. Xing, L., L. Carlson, B. Story, et al. 2003. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for ILalpha/betainduced bone resorption. J. Bone Miner. Res. 18: 260-269.
22. Asagiri, M., K. Sato, T. Usami, et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202: 1261-1269.
23. Yamashita, T., Z. Yao, F. Li, et al. 2007. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282: 18245-18253.
24. Boyce, B.F. &L. Xing. 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473: 139-146.
25. Yao, Z., L. Xing &B.F. Boyce. 2009. NF-B p100 limits TNF-induced bone resorption in mice by a TRAF3- dependent mechanism. J. Clin. Invest. 119: 3024-3034.
26. Fuller, K., C.Murphy, B. Kirstein, et al. 2002. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143: 1108-1118.
27. Darnay, B.G., A. Besse, A.T. Poblenz, et al. 2007. TRAFs in RANK signaling. Adv. Exp. Med. Biol. 597: 152-159.
28. Kanazawa, K. &A. Kudo. 2005. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J. Bone Miner. Res. 20: 840-847.
29. Otero, J.E., S. Dai, D. Foglia, et al. 2008. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator ofNF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J. Biol. Chem. 283: 24546-24553.
30. Ruocco,M.G., S.Maeda, J.M. Park, et al. 2005. I-kappaBkinase (IKK), but not IKK, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201: 1677-1687.
31. Jimi, E., K. Aoki, H. Saito, et al. 2004. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10: 617-624.
32. Aya, K., M. Alhawagri, A. Hagen-Stapleton, et al. 2005. NF-{kappa}B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest. 115: 1848-1854.
33. Vaira, S., M. Alhawagri, I. Anwisye, et al. 2008. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J. Clin. Invest. 118: 2088-2097
34. Vaira, S., T. Johnson, A.C. Hirbe, et al. 2008. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc. Natl. Acad. Sci. USA 105: 3897-3902.
35. Campbell, I.K., S. Gerondakis, K. O'Donnell &I.P. Wicks. 2000. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105: 1799-1806.
36. Li, J., I. Sarosi, X.Q. Yan, et al. 2000.RANKis the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571.
37. He, J.Q., B. Zarnegar, G. Oganesyan, et al. 2006. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J. Exp. Med. 203: 2413-2418.
38. Karsenty, G. &E.F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2: 389-406.
39. Wagner, E.F. &G. Karsenty. 2001. Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11: 527-532.
40. Vu, T.H., J.M. Shipley, G. Bergers, et al. 1998. MMP- 9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422.
41. Provot, S., H. Kempf, L.C. Murtaugh, et al. 2006. Nkx3.2/Bapx1 acts as a negative regulator of chondrocyte maturation. Development 133: 651-662.
42. Park, M., Y. Yong, S.W. Choi, et al. 2007. Constitutive RelA activation mediated by Nkx3.2 controls chondrocyte viability. Nat. Cell Biol. 9: 287-298.
43. Akiyama, H. 2008. Control of chondrogenesis by the transcription factor Sox9.Mod. Rheumatol. 18: 213-219.
44. Seguin, C.A. &S.M. Bernier. 2003. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: Role of MEK1/2 and NF-kappaB signaling pathways. J. Cell Physiol. 197: 356-369.
45. Herman, S., G. Kronke &G. Schett. 2008. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol. Med. 14: 245-253.
46. Pulai, J.I., H. Chen, H.J. Im, et al. 2005. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J. Immunol. 174: 5781-5788.
47. Wehling, N., G.D. Palmer, C. Pilapil, et al. 2009. Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. Arthritis Rheum. 60: 801-812.
48. Bauge, C., J. Attia, S. Leclercq, et al. 2008. Interleukin- 1beta up-regulation of Smad7 via NF-kappaB activation in human chondrocytes. Arthritis Rheum. 58: 221-226.
49. Martel-Pelletier, J., R. McCollum, J. DiBattista, et al. 1992. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum. 35: 530-540.
50. Nam, J., B.D. Aguda, B. Rath &S. Agarwal. 2009. Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling. PLoS One 4: e5262.
51. Chang, J., Z. Wang, E. Tang, et al. 2009. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 15: 682-689.
52. Yamaguchi, M. &M.N. Weitzmann. 2009. The estrogen 17beta-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-kappaB activity. Int. J. Mol. Med. 23: 297-301.
53. Li, Y., A. Li, K. Strait, et al. 2007. Endogenous TNF alpha lowers maximumpeak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J. Bone Miner. Res. 22: 646-655.
54. Eliseev, R.A., E.M. Schwarz, M.J. Zuscik, et al. 2006. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NF-kappaB. Exp. Cell Res. 312: 40-50.
55. Xiao, M., C.E. Inal, V.I. Parekh, et al. 2009. Role of NFkappaB in hematopoietic niche function of osteoblasts after radiation injury. Exp. Hematol. 37: 52-64.
56. Adams, G.B. &D.T. Scadden. 2006. The hematopoietic stem cell in its place. Nat. Immunol. 7: 333-337.
57. Jung, Y., J. Song, Y. Shiozawa, et al. 2008. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 26: 2042-2051.
58. Ahmed, K.M. &J.J. Li. 2008. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic. Biol. Med. 44: 1-13.
59. Garrett, I.R., D. Chen, G. Gutierrez, et al. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111: 1771-1782.
60. Burkiewicz, J.S., S.L. Scarpace &S.P. Bruce. 2009. Denosumabin osteoporosis and oncology.Ann.Pharmacother. 43: 1445-1455.